Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6275195 | 0.77 | LMNA (0.41) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL15570602 | 0.77 | CA1 (0.42) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL28818918 | 0.77 | KMT2A (0.48) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL2360743 | 0.77 | KMT2A (0.43) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL3131540 | 0.75 | KMT2A (0.41) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL11107422 | 0.75 | LMNA (0.43) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL9060085 | 0.74 | KMT2A (0.43) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL6349798 | 0.74 | LMNA (0.39) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL15570666 | 0.74 | CA12 (0.45) | LMNATHRBCYP2C19KMT2ACA12 | |
| SCHEMBL5315502 | 0.73 | LMNA (0.38) | LMNATHRBCYP2C19KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113387927-B | Nitroimidazole derivative for preparing hypoxia imaging agent and preparation method and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2022-10-04 | — | — | CN | disclosed |
| CN-113387927-A | Nitroimidazole derivative for preparing hypoxia imaging agent and preparation method and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2021-09-14 | — | — | CN | disclosed |
| EP-2128140-B1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-8030338-B2 | Method for producing 2-nitroimidazole derivative | POLA PHARMA INC. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | POLA PHARMA INC (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128140-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | Pola Pharma Inc. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004460-A1 | METHOD FOR PRODUCING 2-NITROIMIDAZOLE DERIVATIVE | GALK1, HOGA1, DERA | LMNA 2553/4885THRB 3406/4885CYP2C19 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.